Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 6/20 | 0.53 |
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.41 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.36 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.35 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.35 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.35 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.35 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.35 |
| ▸ | RARG | P13631 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8333731 | 0.93 | PPARG (0.46) | PPARGRARGRXRAKMT2ASMN1; SMN2 | |
| SCHEMBL2085262 | 0.74 | MAPT (0.40) | PPARGKMT2ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL8472017 | 0.72 | POLB (0.45) | KMT2ASMN1; SMN2POLBALDH1A1MAPT | |
| SCHEMBL6891679 | 0.71 | PPARG (0.64) | PPARGRARGRXRAKMT2ASMN1; SMN2 | |
| SCHEMBL8689551 | 0.71 | POLB (0.41) | KMT2APOLBALDH1A1MAPTKDM4E | |
| SCHEMBL3774754 | 0.70 | MAPT (0.50) | KMT2ASMN1; SMN2POLBALDH1A1MAPT | |
| SCHEMBL6032173 | 0.69 | MAPT (0.54) | KMT2APOLBALDH1A1MAPTL3MBTL1 | |
| Rosiglitazone SCHEMBL466397 | 0.69 | PPARG (1.00) | PPARGRARGRXRAKMT2AALDH1A1 | |
| Rosiglitazone SCHEMBL504723 | 0.69 | PPARG (1.00) | PPARGRARGRXRAKMT2AALDH1A1 | |
| Rosiglitazone SCHEMBL5556077 | 0.69 | PPARG (1.00) | PPARGRARGRXRAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5910592-A | STABLE, WATER SOLUBLE COMPOUNDS USED FOR TREATMENT OF TYPE IIDIABETES, ATHEROSCLEROSIS AND EATING DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-08 | — | — | US | disclosed |
| US-5741803-A | Substituted thiazolidinedionle derivatives | SMITHKLINE BEECHAM PLC (GB) | 1998-04-21 | — | — | US | disclosed |